Insight journal - Dealtalk, Pharma

Bio News: Cosmo Pharma talking sale of its cancer detection dye by 2013

Posted on 26 September 2012

Tags: ,

Cosmo Pharmaceuticals SpA (COPN), makes bio news with the potential sale of its dye which may help detect pre-cancerous colon growths.

The CEO, Mauro Ajani said the products potential is sure to lure a buyer for the same  within the year 2013 as further reported in the headline bio news.

More than 10 companies have expressed interest in the dye, called Methylene Blue MMx, and the company expects to start talks before April, Ajani said in an interview at Cosmo’s headquarters in Lainate, near Milan. The company probably won’t sell rights to the product separately because it would reduce the appeal of the company to a potential acquirer, Ajani said.

“Usually a pharma company wants to buy when the company that is going to be bought retains the rights,” he said. “What I can tell you for sure, in one year we will understand what our way out will be.”

Cosmo is preparing to test Methylene Blue MMx in the third and final stage of trials usually required for regulatory approval, and plans to seek marketing clearance in the U.S. and Europe next year, Ajani said. Results from the second stage of tests are expected in the next month, he said. The product may reach $1.5 billion in sales, said Chris Tanner, Cosmo’s chief financial officer.

“We have so many companies that have already shown interest in the project that it should be very easy to find a partner,” Ajani said. “If the outcome is positive, we have a major opportunity to reach an important agreement with a big company.”

Cosmo’s Ownership

Ajani founded Cosmo in 1997, took it public on the Swiss exchange 10 years later and owns 43 percent of the stock. He has an arrangement with other executives that gives him control of 53 percent of the shares, Tanner said.

Cosmo has gained 54 percent this year, compared with a 14 percent gain in the Swiss Performance Index. The stock dropped 0.8 percent to 26.1 Swiss francs as of 9:25 a.m. in Zurich, giving the company a market value of 391 million Swiss francs ($417 million).

Cosmo is testing Methylene Blue MMx as a tablet that patients take before a colonoscopy, the procedure in which surgeons thread a camera through the rectum and colon to look for and remove polyps and lesions, which can become cancerous. About 30 million people will have the procedure this year in the seven largest markets, Ajani said.

White Light

In most cases doctors use white light to check for abnormalities in the colon, said Matt Rutter, a consultant gastroenterologist at the University Hospital of North Tees in the U.K. In as much as 5 percent of cases they use an older form of methylene blue in a spray applied via a catheter that’s inserted with the camera, Rutter said. The process adds about 15 minutes to a standard half-hour procedure, he said.

If it works, Cosmo’s tablet “would speed up the procedure and allow you to focus on detecting the lesions rather than applying the dye,” said Rutter, who’s also a member of the British Society of Gastroenterology committee that sets guidelines for endoscopies in the U.K. He said he has no financial ties to Cosmo.

Currently doctors only use methylene blue in patients who have a tendency to develop pre-cancerous polyps, or who have bowel inflammation that puts them at risk of cancerous changes, Rutter said. Evidence that Cosmo’s product benefits other groups of patients could expand the usage to as much as 20 percent of cases, he said.

“It’s something that is improving an existing procedure and therefore should gain a relatively high acceptance rate and have fast uptake,” Peter Welford, an analyst at Jefferies International Ltd. inLondon, said in a telephone interview.



Read: more on dealtalk  in pharma, biotech, life science partnering deal news, insights and glossary

Report:   Oncology Partnering Terms and Agreements

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply